human colon carcinoma cell line ht29 (ATCC)
Structured Review

Human Colon Carcinoma Cell Line Ht29, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 14124 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cell+line+ht29/HT-29/pmc13201902-60-1-9
Average 99 stars, based on 14124 article reviews
Images
1) Product Images from "PLSCR3 Deficiency Triggers mtDNA‐Driven cGAS‐STING Activation to Potentiate Antitumor Immunity in Colorectal Cancer"
Article Title: PLSCR3 Deficiency Triggers mtDNA‐Driven cGAS‐STING Activation to Potentiate Antitumor Immunity in Colorectal Cancer
Journal: Human Mutation
doi: 10.1155/humu/8545428
Figure Legend Snippet: PLSCR3 deficiency disrupts mitochondrial homeostasis in CRC cells. (A) Western blotting verified the reduction of PLSCR3 protein levels in HT29 cells. (B) RT‐qPCR analysis verified reduction of PLSCR3 mRNA levels normalized to GAPDH compared with negative control (NC) cells ( p < 0.0001, n = 3). (C) Representative JC‐1 staining (scale bar: 20 μ m) images showing red fluorescence (polarized mitochondria) and green fluorescence (depolarized mitochondria). (D) Quantification of the JC‐1 red/green fluorescence intensity ratio. Fluorescence intensity was quantified using ImageJ software as described in the section. (E) Real‐time oxygen consumption rate (OCR) profiles under sequential treatment with oligomycin, FCCP, and rotenone/Antimycin A. (F) Quantification of cytosolic mtDNA by qPCR using the D‐loop ratio in PLSCR3‐knockdown and control cells. Data are presented as mean ± SD from three independent experiments. Statistical significance was determined using an unpaired two‐tailed Student′s t ‐test for two‐group comparisons.
Techniques Used: Western Blot, Quantitative RT-PCR, Negative Control, Staining, Fluorescence, Software, Knockdown, Control, Two Tailed Test
Figure Legend Snippet: PLSCR3 deficiency activates mtDNA‐associated cGAS‐STING signaling. (A) 2 ′ ‐3 ′ ‐cGAMP quantification by ELISA in PLSCR3 knockdown (KD_PLSCR3) HT29 cells and normal controls (NCs) treated with Scramble or dideoxycytidine (DDC) ( p < 0.0001; ns = not significant; n = 3). (B, C) KD_PLSCR3 cells exhibited an elevation in IFN β and CXCL10 production measured by ELISA compared to NC ( p < 0.0001, n = 3). CRISPR‐mediated STING knockout (STING sg) completely abrogated these effects. (D) Western blot analysis showed upregulation of phosphorylated STING and innate immune effectors (IFIH1, ISG60, and ISG15 protein) in STING‐competent KD_PLSCR3 cells relative to GAPDH loading controls. (E) Normalized mRNA level quantification by qPCR demonstrated significant induction of interferon‐stimulated genes (ISGs) in STING‐competent KD_PLSCR3 cells compared with the other groups. Data in panels A–C and E are presented as mean ± SD. Statistical significance was determined using one‐way ANOVA followed by Tukey′s multiple‐comparisons post hoc test for multiple‐group comparisons.
Techniques Used: Enzyme-linked Immunosorbent Assay, Knockdown, CRISPR, Knock-Out, Western Blot
Figure Legend Snippet: PLSCR3 deficiency enhances the sensitivity to immune cell–mediated killing in CRC. (A) Schematic of coculture system: PLSCR3 knockdown (KD_PLSCR3) HT29 cells or control were cocultured with human cord blood–derived NK cells at an E:T ratio of 5:1. (B, C) Phase‐contrast microscopy (scale bar: 50 μ m) showing morphological changes. Morphological analysis demonstrated decreased cell number in KD_PLSCR3 cells in the coculture condition ( p < 0.0001, n = 5). (D) Mouse graft carcinoma with control or PLSCR3 knockout (PLSCR3 sg) CT26 cells were treated with or without anti‐PD‐1 antibodies ( α PD‐1). Tumor growth curves (mm 3 ) were recorded at Days 5, 10, 15, and 20 after tumor cell inoculation in immunocompetent BALB/c mice. (E) At Day 20, terminal tumor weights in the mouse graft carcinoma were measured. (F–H) Flow cytometry analysis of CD4+ and CD8+ tumor‐infiltrating T cells. The representative cell populations of CD4+ and CD8+ are shown. (I, J) Flow cytometry and ELISA analysis of Granzyme B (GZMB) expression ( n = 5). Data are presented as mean ± SD. Tumor growth curves were analyzed using two‐way repeated‐measures ANOVA with post hoc multiple‐comparison tests. For multiple‐group comparisons, including panels I and J, one‐way ANOVA followed by Tukey′s post hoc test was used.
Techniques Used: Knockdown, Control, Derivative Assay, Microscopy, Knock-Out, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Expressing, Comparison
